Since bystander immune cells such as CD4 T-cells promote CLL survival/proliferation in tumour niches before FCR [16], we hypothesised that normal lymphocyte levels may influence the duration of PFS independently of the MRD status achieved after completion of therapy. This evidence concerns the gene CD4 and B-cell chronic lymphocytic leukemia.